1,106 material Form 8-K filings that 909 companies we cover made with the SEC in June 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
United Community Banks agreed on June 11, 2026 to sell Navitas Credit Corp. and NLFC Reinsurance Corp., its equipment finance lending and reinsurance subsidiaries, to Navitas TopCo LLC, an entity tied to funds managed by Wafra Inc. The estimated cash purchase price is $1.9 billion, based on March 31, 2026 financials, and the company expects a one-time pre-tax earnings benefit of $109 million and a 145 basis point CET1 capital gain, while the equipment finance business accounts for about 50% of trailing net charge-offs despite being 10% of loans. Closing is expected in the third quarter of 2026 and is subject to regulatory approvals and other customary conditions.
Estimated purchase price of $1.9 billion, a 7% premium to par value of the Navitas loan portfolio; final price subject to closing adjustments
Expected one-time pre-tax earnings benefit of $109 million and about 3% accretion to tangible book value per share, per the investor presentation
Equipment finance is 10% of total loans but about 50% of net charge-offs for the twelve months ended March 31, 2026
Expected to close in Q3 2026; Purchaser must pay a $17.5 million termination fee in specified circumstances; agreement can be terminated if not completed by December 11, 2026
On June 11, 2026, Dianthus Therapeutics posted an updated corporate presentation with interim responder analysis for the first 40 patients to complete Part A of the Phase 3 CAPTIVATE trial of claseprubart in chronic inflammatory demyelinating polyneuropathy (CIDP). The presentation reports a 75% response rate, and the company says it supports potential best-in-disease efficacy. The filing notes the analysis covers a limited number of patients and may not predict results for remaining Part A patients or Part B.
Observed 75% response rate from the first 40 participants to complete CAPTIVATE Part A, per the presentation.
Company guidance: Phase 3 CIDP Part B top-line guidance by year-end 2026.
Cash, cash equivalents and investments of about $1.2 billion as of March 31, 2026, with runway expected into 2030.
Presentation filed as Exhibit 99.1, dated June 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.